FCM
PLRX icon

Farallon Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Farallon Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-490,000
Closed -$14.3M – 309
2021
Q2 		$14.3M Sell
490,000
-274,262
-36% -$8.54M 0.06% 116
2021
Q1 		$30.1M Hold
764,262
– – 0.15% 87
2020
Q4 		$17.4M Hold
764,262
– – 0.1% 92
2020
Q3 		$17.3M Sell
764,262
-86,539
-10% -$2.16M 0.12% 88
2020
Q2 		$27.6M Buy
+850,801
New +$22.6M 0.22% 77

Other funds holding PLRX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Farallon Capital Management's PLRX Position: Q3 2021 in Review

Farallon Capital Management sold out of Pliant Therapeutics (PLRX) in Q3 2021, closing a stake of 490,000 shares — an estimated $14.3M sold.

Farallon Capital Management first reported a position in PLRX in Q2 2020 and held it in 5 quarters. The position peaked at $30.1M in Q1 2021. 77 funds tracked by Wall St. Rank hold PLRX as of Q3 2021.

  • Farallon Capital Management reported no remaining Pliant Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Farallon Capital Management sold 490,000 Pliant Therapeutics shares in Q3 2021, an estimated $14.3M.
  • Farallon Capital Management first reported a position in Pliant Therapeutics in Q2 2020 and held it in 5 quarters.
  • Farallon Capital Management's Pliant Therapeutics position peaked at $30.1M in Q1 2021.
  • 77 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2021.

Based on Farallon Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.